Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017

Chen, Alice J; Hu, Xiaohan; Conti, Rena M.; Jena, Anupam B.; Goldman, Dana P.

doi:10.1016/j.jval.2019.08.005

Cited by 9 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between 2010 and 2017, 53 out of the 105 new cancer drugs approved are delivered in an oral formulation. 4 Nearly half of the molecules in the late-phase oncology pipeline in 2018 were oral targeted small molecules or hormonals. 5…”

Section: Introductionmentioning

confidence: 99%

Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer

Liao

Pan

et al. 2022

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE: The rapidly rising costs of targeted oral anticancer medicines (TOAMs) raise concerns over their affordability. Our goal was to examine recent trends in the uptake of TOAMs among cancer patients with Medicare Part D, the share of TOAM users who reached catastrophic coverage, and the annual spending on TOAMs in the catastrophic phase. METHODS: Using the 5% SEER-Medicare, we included patients age 65 years and older who had one primary cancer diagnosis between 2011 and 2016. We included person-years where patients were enrolled in a Part D plan for the entire year, did not receive the low-income subsidy at any time of the year, and received anticancer systemic therapies. We estimated the trends in the share of patients who used TOAMs, the percentage of TOAM users reaching catastrophic coverage, and the total and patient out-of-pocket spending on TOAMs in the catastrophic phase in a year. RESULTS: From 2011 to 2016, the uptake of TOAMs among our study population increased from 3.6% to 8.9%. The percentage of non–low-income subsidy TOAM users who reached catastrophic coverage increased from 54.6% to 60.3%. Among those who reached the catastrophic phase, mean total gross spending on TOAMs in the catastrophic phase increased from $16,074 (USD) to $64,233 (USD) and mean patient out-of-pocket spending from $596 (USD) to $2,549 (USD). The mean 30-day total spending increased from $4,011 (USD) to $8,857 (USD), and the mean 30-day out-of-pocket spending from $154 (USD) to $328 (USD). CONCLUSION: The high and growing burden from TOAMs highlighted the need for reining in drug prices and capping out-of-pocket spending.

show abstract

Section: Introductionmentioning

confidence: 99%

Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer

Liao

Pan

et al. 2022

JCO Oncology Practice

View full text Add to dashboard Cite

show abstract

“…In this paper, we studied treatment patterns, overall survival, and Medicare spending among older adults diagnosed with advanced NSCLC in 2012‐2015 and examined changes following the introduction of immune checkpoint inhibitors. In the United States, the rapid adoption of high‐cost immune checkpoint inhibitors for advanced NSCLC has raised important policy questions regarding the balance of benefits and costs of these treatments 11‐15 . Patients with advanced NSCLC treated with immune checkpoint inhibitors in routine practice are significantly older than those who participated in clinical trials, 4,6‐8 further highlighting the need to study the population‐level impact of the introduction of these therapies.…”

Section: Introductionmentioning

confidence: 99%

“…Patients with advanced NSCLC treated with immune checkpoint inhibitors in routine practice are significantly older than those who participated in clinical trials, 4,6‐8 further highlighting the need to study the population‐level impact of the introduction of these therapies. Our study of novel immunotherapies for advanced NSCLC also provides an example for evaluating the population‐level impacts of other high‐cost cancer therapies in the United States 13‐15 …”

Section: Introductionmentioning

confidence: 99%

“…In the United States, the rapid adoption of high-cost immune checkpoint inhibitors for advanced NSCLC has raised important policy questions regarding the balance of benefits and costs of these treatments. [11][12][13][14][15] Patients with advanced NSCLC treated with immune checkpoint inhibitors in routine practice are significantly older than those who participated in clinical trials, 4,[6][7][8] further highlighting the need to study the population-level impact of the introduction of these therapies. Our study of novel immunotherapies for advanced NSCLC also provides an example for evaluating the population-level impacts of other high-cost cancer therapies in the United States.…”

Section: Introductionmentioning

confidence: 99%

“…Our study of novel immunotherapies for advanced NSCLC also provides an example for evaluating the population-level impacts of other high-cost cancer therapies in the United States. [13][14][15]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations